Skip to Main Content

Paper Details

KIT<sup>low</sup> Cells Mediate Imatinib Resistance in Gastrointestinal Stromal Tumor.
Mol Cancer Ther
8
2021
AXL, CD34, CD34+KIThigh progeny, CD34+KITlow cell population, CD34+KITlow cells, CD34+KITlow human GIST cells, GIST, GIST cell lines, Gas6, Gastrointestinal Stromal Tumor, Gastrointestinal stromal tumor, IM-resistant GIST cells, Imatinib, KIT, KIThigh, KITlow, KITlow Cells, NANOG, NF-B, NF-B signaling gene, OCT4, Onco, Tumors, bardoxolone, bemcentinib, cancer, cancer stem, cancer stem cell, cancer stem cell gene signatures, human, imatinib, oncogenic KIT mutations, primary IM-resistant GIST cells, transcriptomic-oncogenic map, tumors, tyrosine, tyrosine kinase
Author NameAffiliation
Huwate YeernaMoores Cancer Center, University of California
Huwate YeernaUniversity of California
Jill P MesirovMoores Cancer Center, University of California
Jill P MesirovUniversity of California
Jill P MesirovMoores Cancer Center, University of California
Jill P MesirovUniversity of California
Robert J Wechsler-ReyaSanford Burnham Prebys Medical Discovery Institute
Robert J Wechsler-ReyaSanford Burnham Prebys Medical Discovery Institute
Pablo TamayoMoores Cancer Center, University of California
Pablo TamayoUniversity of California
Pablo Tamayouniversity of california san diego Center for Novel Therapeutics
Pablo TamayoMoores Cancer Center, University of California
Pablo TamayoUniversity of California
Pablo Tamayouniversity of california san diego Center for Novel Therapeutics
  • 1 - 14

Datasets

Release 1.2